New CMPI Report Presents First Estimates of the Potential Economic Impact That New Treatments for Alzheimer's Disease Could Have on the U.S. Economy
Who: ACT-AD and Alliance for Aging Research; The Center for Medicine in the Public Interest
What: New Report Launch: Press Conference and Lunch:
- New medication can stave off onset of Alzheimer’s, extending lives, saving money
- Report discusses ways to give more power to older consumers in an aging society
Where: National Press Club
529 14th Street NW – Washington, DC
Lisagor Room
When: Monday, May 14, 2007, 12:00 pm press conference and lunch
RSVP: Nicholas Terzulli, (212) 588-9148 / nterzulli@capitalhq.com
Speakers:
-- Meryl Comer, Alzheimer’sAssociation National Capital Area Chapter Board Member, and Emmy-award-winning reporter, producer, moderator; also the principal caregiverfor herhusband who has advanced Alzheimer’s.
-- Robert Goldberg, Ph.D.,Vice President and Director of Programs for the Center for Medicine in thePublic Interest.
-- Daniel Perry, Chair of theACT-AD Coalition and Executive Director of the non-profit organization Alliance for Aging Research.
-- Peter Pitts, President of Center for Medicine in the Public Interest and former FDA Associate Commissioner for External Relations
-- John Vernon, Ph.D., Assistant Professor in the Finance Department at the University of Connecticut School of Business.
About the Report
One in 10 people over 65 – or 5.6 million Americans – will have Alzheimer’s Disease by 2010. Without interventional therapy, the number of cases is expected to rise to 13.5 million by 2050. Currently available treatments for Alzheimer’s disease provide only temporary symptomatic relief and only for some patients, while therapies under FDA review may significantly delay or reverse the course of the disease. This report presents the first scientific estimates of the potential economic impact that new treatments for Alzheimer's disease could have on the U.S. economy. The study was sponsored by ACT-AD, a coalition of 49 national organizations seeking to accelerate development of potential cures and treatments for Alzheimer’s disease. The report will also be posted and made available through the National Bureau of Economic Research.
Who: ACT-AD and Alliance for Aging Research; The Center for Medicine in the Public Interest
What: New Report Launch: Press Conference and Lunch:
- New medication can stave off onset of Alzheimer’s, extending lives, saving money
- Report discusses ways to give more power to older consumers in an aging society
Where: National Press Club
529 14th Street NW – Washington, DC
Lisagor Room
When: Monday, May 14, 2007, 12:00 pm press conference and lunch
RSVP: Nicholas Terzulli, (212) 588-9148 / nterzulli@capitalhq.com
Speakers:
-- Meryl Comer, Alzheimer’sAssociation National Capital Area Chapter Board Member, and Emmy-award-winning reporter, producer, moderator; also the principal caregiverfor herhusband who has advanced Alzheimer’s.
-- Robert Goldberg, Ph.D.,Vice President and Director of Programs for the Center for Medicine in thePublic Interest.
-- Daniel Perry, Chair of theACT-AD Coalition and Executive Director of the non-profit organization Alliance for Aging Research.
-- Peter Pitts, President of Center for Medicine in the Public Interest and former FDA Associate Commissioner for External Relations
-- John Vernon, Ph.D., Assistant Professor in the Finance Department at the University of Connecticut School of Business.
About the Report
One in 10 people over 65 – or 5.6 million Americans – will have Alzheimer’s Disease by 2010. Without interventional therapy, the number of cases is expected to rise to 13.5 million by 2050. Currently available treatments for Alzheimer’s disease provide only temporary symptomatic relief and only for some patients, while therapies under FDA review may significantly delay or reverse the course of the disease. This report presents the first scientific estimates of the potential economic impact that new treatments for Alzheimer's disease could have on the U.S. economy. The study was sponsored by ACT-AD, a coalition of 49 national organizations seeking to accelerate development of potential cures and treatments for Alzheimer’s disease. The report will also be posted and made available through the National Bureau of Economic Research.
